This one comes in from Agora, selling us Christopher Hancock’s Free Market Investor. Hancock is fairly new on the scene, but I have been intrigued by the one other idea of his that I sleuthed out several months ago (back then he was selling the “Secret Pension Payout Plan.”) You’ll also see this teased as […]
Articles
This is one I’m surprised I never got around to doing before — but I just had it sent to me again, and I know I’ve been seeing it fairly consistently since mid-May or so, so I might as well give it a quick writeup here. It was actually teased in the same ad as […]
This one was talked up on the Gumshoe forum a little bit, and forum member jg gave me the key clue to get me over the hump to sleuth it out for you. This one has nagged at me for a little while, so I like this forum business already! Here’s what we’ve got: An […]
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
Setting aside how most Gumshoers regard Altucher, SSTI had a wonderful price run up in Jan 2019 and then based/traded si...
Travis, Here is a summary of IIPR's recent activity (2/13/19) from Briefing.com which (as it seems to me) is causing the...
I don't like Yahoo Finance much anymore, they no longer collect much useful information outside of the basic fundamental...
My favorite summary sources for that kind of basic info are YCharts and Briefing.com, though neither is free....
FYI, I saw a news brief dated 1/9/2018 stating "BIVV ...will acquire all shares in FIVE Inc, making it a subsidiary of t...
Another note about the focus on this sector, from briefing.com this morning: Qualcomm Incorporated (QCOM...
$SNNA No Position From Briefing.com STORY STOCKS® | Updated: 21-Aug-17 | Archive | Add to Column Alerts Brief...
$ AFMD long From Briefing.com Exelixis (EXEL) initiated with Buy and $33 tgt, Affimed Therapeutics (AFMD) with Buy...
$SCYX Briefing.com in-play article: --The first oral presentation (#OS0846) described new data from a multicenter ...
$AKAO: -How much weight should one place on financial analyst opinions on stock recommendations? IMO, this provides th...
Here's the first really optimistic growth forecast I've seen for STM lately, based largely on the fact that they've appa...
Update today from Briefing.com: Himax Tech target raised to $14 at Craig Hallum -- It’s looking more an...
Actinum Pharma to provide clinical update on Actimab-A at upcoming 2015 ASCO annual meeting on Sunday, May 31 Briefing....
Also Robert Re; $NBY Briefing.com is reporting that shares were halted at 3:43PM because of good news. http://finance.y...
Akebia Therapeutics misses by $0.02 Briefing.com - 7:05 AM ET, 11/10/2014 Reports Q3 (Sep) loss of $0.47 per share...
YES!!!! Durata Therapeutics to be acquired by Actavis (ACT) for $23.00/share in cash, or ~$675 million in the aggregate...